Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 CLINICAL TRIAL MARKET FOR EUROPE IRON-DEFICIENCY ANEMIA THERAPY
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR EUROPE IRON-DEFICIENCY ANEMIA THERAPY
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
13 ASSET-BASED COLLABORATIONS AND PARTNERSHIPSMARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINS
13.3 OPPURTUNITY
13.4 CHALLENGES
14 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY TYPE
14.1 OVERVIEW
14.2 ORAL IRON THERPAY
14.2.1 FERROUS SULFATE
14.2.1.1. BY DOSAGE FORM
14.2.1.1.1. CAPSULE
14.2.1.1.2. TABLET
14.2.2 FERROUS GLUCONATE
14.2.2.1. BY DOSAGE FORM
14.2.2.1.1. CAPSULE
14.2.2.1.2. TABLET
14.2.3 FERROUS FUMARATE
14.2.3.1. BY DOSAGE FORM
14.2.3.1.1. CAPSULE
14.2.3.1.2. TABLET
14.2.4 POLYSACCHARIDE IRON COMPLEX (PIC)
14.2.4.1. BY DOSAGE FORM
14.2.4.1.1. CAPSULE
14.2.4.1.2. TABLET
14.2.5 OTHERS
14.2.5.1. OVER THE COUNTER DRUGS
14.2.5.2. OFF-LABEL GENERIC DRUGS
14.3 PARENTRAL IRON THERAPY
14.3.1 IRON DEXTRAN
14.3.2 IRON SUCROSE
14.3.3 FERRIC GLUCONATE
14.3.4 SODIUM FERRIC GLUCONATE COMPLEX
14.3.5 IRON ISOMALTOSIDE
14.4 ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) THERAPY
14.4.1 BY ROUTE OF ADMINISTRTAION
14.4.1.1. INTRAVENOUS
14.4.1.2. SUBCUTANEOUS
14.5 OTHERS
15 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE
15.1 OVERVIEW
15.2 BRANDED
15.3 GENERIC
16 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY APPLICATION
16.1 OVERVIEW
16.2 INFLAMMATORY BOWEL DISEASE
16.2.1 ORAL IRON SUPPLEMENTS THERAPY
16.2.2 PARENTERAL IRON THERAPY
16.2.3 OTHERS
16.3 RENAL
16.3.1 ORAL IRON SUPPLEMENTS THERAPY
16.3.2 PARENTERAL IRON THERAPY
16.3.3 OTHERS
16.4 OBSTETRICS
16.4.1 ORAL IRON SUPPLEMENTS THERAPY
16.4.2 PARENTERAL IRON THERAPY
16.4.3 OTHERS
16.5 GYNECOLOGY
16.5.1 ORAL IRON SUPPLEMENTS THERAPY
16.5.2 PARENTERAL IRON THERAPY
16.5.3 OTHERS
16.6 CONGESTIVE HEART FAILURE (CHF)
16.6.1 ORAL IRON SUPPLEMENTS THERAPY
16.6.2 PARENTERAL IRON THERAPY
16.6.3 OTHERS
16.7 ONCOLOGY
16.7.1 ORAL IRON SUPPLEMENTS THERAPY
16.7.2 PARENTERAL IRON THERAPY
16.7.3 OTHERS
16.8 OTHERS
17 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY CONDITION
17.1 OVERVIEW
17.2 MILD
17.3 MODERATE
17.4 SEVERE
18 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY AGE GROUP
18.1 OVERVIEW
18.2 PEDIATRIC
18.3 ADULTS
18.4 GERIATRICS
19 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.3 FEMALE
20 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.3 SPECIALTY CLINICS
20.4 HOMECARE SETTING
20.5 OTHERS
21 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 HOSPITALS PHARMACY
21.3 ONLINE PHARMACY
21.4 RETAIL PHARMACY
21.5 OTHERS
22 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY GEOGRAPHY
EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1 EUROPE
22.1.1 GERMANY.
22.1.1.1. GERMANY . IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY TYPE
22.1.1.2. GERMANY . IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY CONDITION
22.1.1.3. GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY AGR GROUP
22.1.1.4. GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY GENDER
22.1.1.5. GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER
22.1.1.6. GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL
22.1.2 FRANCE
22.1.3 U.K.
22.1.4 ITALY
22.1.5 SPAIN
22.1.6 RUSSIA
22.1.7 TURKEY
22.1.8 BELGIUM
22.1.9 NETHERLANDS
22.1.10 SWITZERLAND
22.1.11 REST OF EUROPE
22.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, SWOT AND DBMR ANALYSIS
24 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: EUROPE
24.2 MERGERS & ACQUISITIONS
24.3 NEW PRODUCT DEVELOPMENT & APPROVALS
24.4 EXPANSIONS
24.5 REGULATORY CHANGES
24.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, COMPANY PROFILE
25.1 ABBOTT
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 SANOFI
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 COVIS PHARMA GMBH
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 DAIICHI SANKYO, INC
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 PHARMACOSMOS THERAPEUTICS INC
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 ABBVIE.
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 NOVARTIS AG
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 LUPIN
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 CSL VIFOR
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 SHIELD THERAPEUTICS PLC
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 ALKEM LABORATORIES LTD.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 KERYX BIOPHARMACEUTICALS, INC. (AKEBIA THERAPEUTICS INC)
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.12.6
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
